^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
M9466
i
Other names: M9466, HRS-1167
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EMD Serono, Jiangsu Hengrui Pharma
Drug class:
PARP1 inhibitor
Related drugs:
29d
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
P1/2, N=54, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
Avastin (bevacizumab) • M9466
2ms
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
P1/2, N=54, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1/2 trial • Combination therapy
|
Avastin (bevacizumab) • M9466
2ms
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
P1, N=18, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
Trial completion
|
M9466 • rifampicin
4ms
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
M9466 • rifampicin
4ms
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1 trial
|
M9466 • rifampicin
over1year
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=153, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HRD (Homologous Recombination Deficiency)
|
M9466
almost2years
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=153, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1 trial
|
HRD (Homologous Recombination Deficiency)
|
M9466
Share via
